DiabetesNCT00205335
Free Test Strips and Blood Glucose Control
A study testing Ascencia Breeze Glucose meter and Breeze Glucose Monitor (Bayer) in people with Diabetes, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
This study is designed to determine if there is an impact on blood glucose control in patients who receive free test strips. Patients in the study have no insurance or insurance that does not cover the purchase of test strips. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes
- What is being tested?
- Ascencia Breeze Glucose meter and Breeze Glucose Monitor (Bayer)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2004to Nov 2007
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with a diagnosis of diabetes who have no health insurance or insurance that does not pay for purchase of blood test strips
Who cannot join
- Patients with a diagnosis of diabetes who have health insurance that pays for purchase of blood test strips
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Increased Availability of Test Strips on Blood Glucose Control in Patients With Diabetes
This study is designed to determine if there is an impact on blood glucose control in patients who receive free test strips. Patients in the study have no insurance or insurance that does not cover the purchase of test strips. A comparison of weight, blood pressure, and Hemoglobin A1C from entry to the final visit will be used to compare patients' management of their diabetes. Recommended values for these parameters will be used as the standard for comparisons. The investigators anticipate that patients receiving free test strips will show an improvement in the listed parameters as well as in satisfaction with their care.
Read the detailed description
According to the National Institutes of Diabetes and Digestive and Kidney Diseases, an estimated 16 million people in the United States have diabetes mellitus. About one third of these people don't know they have diabetes and are therefore, not receiving treatment. Another 798,000 people are diagnosed with diabetes each year.
Diabetes is the fourth leading cause of death in Wisconsin, as stated at the Wisconsin Department of Health and Family Services website. Diabetes costs an estimated annual $2.1 billion in health care costs and lost productivity. Each year, over 3,600 Wisconsin residents die from diabetes. Others experience disabling complications, including blindness, amputations, heart and kidney disease. In 1998, in Dane County alone, the direct costs of diabetes were estimated at $82.0 million and indirect costs at $100.4 million.
Two landmark studies in the United States and the United Kingdom proved that the level of blood sugar control predicts the onset and severity of diabetes-related complications for both Type 1 and Type 2 diabetes. Thus, people who are able to keep their blood sugars as close to normal as possible can reduce their risks of complications and live relatively "normal" lives. Moreover, the costs to the community will also be reduced.
In order to do this, persons with diabetes need to test blood sugar levels multiple times per day. There are a variety of meters available for testing. Many people have insurance that covers the cost of the meters and related test strips. For those who do not have this coverage, meters are often available free of charge. Unfortunately, this is not true of the test strips, which average $1 each. A person testing four times a day, seven days a week would need almost $1470 to purchase strips for a year.
In the past year, the investigators have seen 35 patients followed in either the East or West Diabetes Clinics who do not have insurance and thus, no way to pay for test strips. It can be assumed that without an adequate number of test strips, these patients are not getting the necessary information to achieve optimal blood sugar control. This puts them at risk for more complications of their diabetes with concurrent emotional and financial costs to them and their families. Further, the cost to the community in the long run is increased.
- Describe the design of your study. Use care to distinguish experimental interventions from standard medical treatment. Specifically include the following information:
The investigators will enroll 35 subjects identified in either the East or West diabetes clinic who do not have insurance or who are underinsured. Underinsured indicates patients with insurance that does not cover the purchase of test strips. Certified Diabetes Educators (CDE) identified other patients after an initial visit when lack of adequate insurance coverage was noted. The list of identified patients was sent to the patient's physician and CDE. Two patients were eliminated who are self-pay by choice; they are self-employed and have adequate resources. Other subjects were eliminated for the following criteria: discharge from UWHC Diabetes Clinic to a primary care provider; patients whose diabetes is controlled by diet alone; patients who are incarcerated and currently have coverage through the penal system.
Subjects will be provided a voucher to obtain free test strips. Subjects routinely return to the clinic at 4-month intervals (study entry, months 4,8,12). During these visits subjects will undergo a Hemoglobin A1C, check height, weight, and blood pressure and complete satisfaction questionnaires at study entry and month 12. Only the questionnaires would not be considered standard of care.
- What method(s) will you use to recruit subjects? Will these methods involve material inducements? Subjects who meet the eligibility criteria will be offered participation. Subjects will receive testing strips, clinic visits at entry and at months 4,8 and 12 and Hemoglobin A1C (HA1C) testing at the above intervals free of charge.
- Does your study have a statistical justification for its sample size? For the analysis of its results? If you answer "yes" to these questions, briefly describe each justification.
No
- Identify the potential risks to subjects of participation in your study. Describe the expected frequency, severity, and reversibility of the major risks you identify. Include possible late effects of participation (e.g., secondary cancers).
All subject records will be kept strictly confidential according to HIPPA privacy rules. Subject records will contain only a study number. The key to the study numbering will be kept in a locked filing cabinet. Subjects may experience slight pain and bruising from the blood draws of the HA1C.
- Identify the expected benefits to subjects of participation in your study. Also identify any potential scientific benefits produced by your study.
Subjects will receive free testing strips and free HA1C testing for a year. Subjects may experience better control of their diabetes as a result of testing their blood sugar levels.
- Describe the procedure for obtaining the consent of each subject or the subject's parent or representative. Confirm that you have attached a copy of each consent form. The form should include all the elements of consent listed in the HSC Guidelines.
Subjects will be given the informed consent and allowed ample time to read the informed consent or have it read to them. Once the consent form has been read subjects will have as much time as needed to ask any questions they may have. Once the subject has had all of their questions answered and agrees to participate the subject will sign the consent form in the presence of the PI or a delegate. Subjects will be given a copy of the signed consent form for their records.
- Conditions
- Diabetes
- Being tested
- Ascencia Breeze Glucose meter, Breeze Glucose Monitor (Bayer)
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ascencia Breeze Glucose meterDevice
Also called Ascencia Breeze glucose meters made by Bayer and test strips
All study participants received glucose meter and test strips.
Breeze Glucose Monitor (Bayer)Device
Also called Ascencia Breeze Glucose Meter, Bayer
Each participant received a Breeze monitor and glucose test strips.
| Study group | Role | What they receive |
|---|---|---|
| glucose monitoring | Other | Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar. Receives: Device: Ascencia Breeze Glucose meter; Device: Breeze Glucose Monitor (Bayer) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight
Measured: one year
Blood pressure
Measured: one year
Hemoglobin A1C
Measured: one year
Secondary outcomes (1)
Satisfaction with care
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2005 (estimated)
- Study startJan 2004
- Primary completionNov 2007
- Study completionNov 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sherree Drezner, ACSW, LCSW, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00205335
- Sponsor's protocol ID
- M-2004-1069
- Status last verified
- Sep 2015
- First submitted
- 13 Sep 2005
- Last updated
- 1 Oct 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Increased Availability of Test Strips on Blood Glucose Control in Patients With Diabetes
- ClinicalTrials.gov ID
- NCT00205335
- Acronym / sponsor ID
- M-2004-1069
- Conditions
- Diabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- Jan 2004
- Primary completion
- Nov 2007 (actual)
- Study completion
- Nov 2007 (actual)
- First posted
- 20 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to determine if there is an impact on blood glucose control in patients who receive free test strips. Patients in the study have no insurance or insurance that does not cover the purchase of test strips. A comparison of weight, blood pressure, and Hemoglobin A1C from entry to the final visit will be used to compare patients' management of their diabetes. Recommended values for these parameters will be used as the standard for comparisons. The investigators anticipate that patients receiving free test strips will show an improvement in the listed parameters as well as in satisfaction with their care.
Detailed description
According to the National Institutes of Diabetes and Digestive and Kidney Diseases, an estimated 16 million people in the United States have diabetes mellitus. About one third of these people don't know they have diabetes and are therefore, not receiving treatment. Another 798,000 people are diagnosed with diabetes each year.
Diabetes is the fourth leading cause of death in Wisconsin, as stated at the Wisconsin Department of Health and Family Services website. Diabetes costs an estimated annual $2.1 billion in health care costs and lost productivity. Each year, over 3,600 Wisconsin residents die from diabetes. Others experience disabling complications, including blindness, amputations, heart and kidney disease. In 1998, in Dane County alone, the direct costs of diabetes were estimated at $82.0 million and indirect costs at $100.4 million.
Two landmark studies in the United States and the United Kingdom proved that the level of blood sugar control predicts the onset and severity of diabetes-related complications for both Type 1 and Type 2 diabetes. Thus, people who are able to keep their blood sugars as close to normal as possible can reduce their risks of complications and live relatively "normal" lives. Moreover, the costs to the community will also be reduced.
In order to do this, persons with diabetes need to test blood sugar levels multiple times per day. There are a variety of meters available for testing. Many people have insurance that covers the cost of the meters and related test strips. For those who do not have this coverage, meters are often available free of charge. Unfortunately, this is not true of the test strips, which average $1 each. A person testing four times a day, seven days a week would need almost $1470 to purchase strips for a year.
In the past year, the investigators have seen 35 patients followed in either the East or West Diabetes Clinics who do not have insurance and thus, no way to pay for test strips. It can be assumed that without an adequate number of test strips, these patients are not getting the necessary information to achieve optimal blood sugar control. This puts them at risk for more complications of their diabetes with concurrent emotional and financial costs to them and their families. Further, the cost to the community in the long run is increased.
- Describe the design of your study. Use care to distinguish experimental interventions from standard medical treatment. Specifically include the following information:
The investigators will enroll 35 subjects identified in either the East or West diabetes clinic who do not have insurance or who are underinsured. Underinsured indicates patients with insurance that does not cover the purchase of test strips. Certified Diabetes Educators (CDE) identified other patients after an initial visit when lack of adequate insurance coverage was noted. The list of identified patients was sent to the patient's physician and CDE. Two patients were eliminated who are self-pay by choice; they are self-employed and have adequate resources. Other subjects were eliminated for the following criteria: discharge from UWHC Diabetes Clinic to a primary care provider; patients whose diabetes is controlled by diet alone; patients who are incarcerated and currently have coverage through the penal system.
Subjects will be provided a voucher to obtain free test strips. Subjects routinely return to the clinic at 4-month intervals (study entry, months 4,8,12). During these visits subjects will undergo a Hemoglobin A1C, check height, weight, and blood pressure and complete satisfaction questionnaires at study entry and month 12. Only the questionnaires would not be considered standard of care.
- What method(s) will you use to recruit subjects? Will these methods involve material inducements? Subjects who meet the eligibility criteria will be offered participation. Subjects will receive testing strips, clinic visits at entry and at months 4,8 and 12 and Hemoglobin A1C (HA1C) testing at the above intervals free of charge.
- Does your study have a statistical justification for its sample size? For the analysis of its results? If you answer "yes" to these questions, briefly describe each justification.
No
- Identify the potential risks to subjects of participation in your study. Describe the expected frequency, severity, and reversibility of the major risks you identify. Include possible late effects of participation (e.g., secondary cancers).
All subject records will be kept strictly confidential according to HIPPA privacy rules. Subject records will contain only a study number. The key to the study numbering will be kept in a locked filing cabinet. Subjects may experience slight pain and bruising from the blood draws of the HA1C.
- Identify the expected benefits to subjects of participation in your study. Also identify any potential scientific benefits produced by your study.
Subjects will receive free testing strips and free HA1C testing for a year. Subjects may experience better control of their diabetes as a result of testing their blood sugar levels.
- Describe the procedure for obtaining the consent of each subject or the subject's parent or representative. Confirm that you have attached a copy of each consent form. The form should include all the elements of consent listed in the HSC Guidelines.
Subjects will be given the informed consent and allowed ample time to read the informed consent or have it read to them. Once the consent form has been read subjects will have as much time as needed to ask any questions they may have. Once the subject has had all of their questions answered and agrees to participate the subject will sign the consent form in the presence of the PI or a delegate. Subjects will be given a copy of the signed consent form for their records.
Study design
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| glucose monitoring | Other | Device: Ascencia Breeze Glucose meter, Device: Breeze Glucose Monitor (Bayer)Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with a diagnosis of diabetes who have no health insurance or insurance that does not pay for purchase of blood test strips
Key exclusion criteria (1 listed)
- Patients with a diagnosis of diabetes who have health insurance that pays for purchase of blood test strips
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ascencia Breeze Glucose meterAlso: Ascencia Breeze glucose meters made by Bayer and test stripsAll study participants received glucose meter and test strips. | Device | glucose monitoring |
| Breeze Glucose Monitor (Bayer)Also: Ascencia Breeze Glucose Meter, BayerEach participant received a Breeze monitor and glucose test strips. | Device | glucose monitoring |
Primary outcome
Weight
Time frame: one year
Blood pressure
Time frame: one year
Hemoglobin A1C
Time frame: one year
1 secondary outcome
Satisfaction with care
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2015.
Related trials for Diabetes
Recruiting
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Heart Failure, Diabetes
Not yet recruiting
STRONG: SMART Trial
Gestational Diabetes Mellitus (GDM)
Recruiting
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
Type 2 Diabetes
Active, not recruitingPhase 4
Pentoxifylline in Diabetic Kidney Disease
Diabetic Kidney Disease
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sherree Drezner, ACSW, LCSW principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ascencia Breeze Glucose meter and Breeze Glucose Monitor (Bayer) in people with Diabetes, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight (time frame: one year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2015.